Business
Bellus Health Announces Payment to Thallion CVR Holders
Bellus Health Announces Payment to Thallion CVR Holders Canada NewsWire LAVAL, Q...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nBellus Health Announces Payment to Thallion CVR Holders\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, Feb. 17, 2017\n\n\n\nThe Company received funds in relation to the 2009 Thallion transaction and a payment of $577,152 will be made to the CVR holders on March 10, 2017\n\n\n\nLAVAL, QC, Feb. 17, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a drug development company focused on rare diseases, today announced that it received $572,586 as additional purchase price consideration in relation to the 2009 Thallion Pharmaceuticals Inc. (Thallion) transaction (the Additional Consideration Payment). This amount will be paid in full to the Contingent Value Rights (CVR) holders, as provided in the agreements of the 2013 Thallion acquisition by BELLUS Health. \n\nIn total, an amount of $577,152 ($0.01609 per CVR) will be paid on March 10, 2017, to CVR holders of record on February 17, 2017. In addition to the Additional Consideration Payment, BELLUS Health will remit to CVR holders $50,000 in relation to the replacement cost of Shigamab antibodies, and will deduct $28,458 of CVR agent costs, $13,404 of undisclosed liability not included in the 2013 Thallion Statement of Net cash and $3,572 of expenses in relation to the unsuccessful listing of the CVR on the Toronto Stock Exchange, all in accordance with the terms of the agreements of the 2013 Thallion acquisition by BELLUS Health. \n\nAbout BELLUS Health (www.bellushealth.com)\n\nBELLUS Health is a drug development company focused on rare diseases. Its pipeline of rare disease projects includes KIACTA™ for the treatment of sarcoidosis and clinical-stage Shigamab™ for sHUS. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. BELLUS Health also has economic interests in several other partnered drug development projects.\n\nForward-Looking Statements\n\nCertain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereo...